Nalaganje...
Carfilzomib for relapsed and refractory multiple myeloma
Although the prognosis of multiple myeloma (MM) patients has dramatically improved during recent years, virtually all patients eventually develop relapsed refractory disease. Several new therapeutics have been developed in the last few years, including carfilzomib, a second-generation proteasome inh...
Shranjeno v:
| izdano v: | Cancer Manag Res |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6450182/ https://ncbi.nlm.nih.gov/pubmed/31037034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S150653 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|